Meibomian Gland Dysfunction Market

Market Overview:

The 7 major meibomian gland dysfunction markets reached a value of US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 4.5 Billion by 2034, exhibiting a growth rate (CAGR) of 7.07% during 2024-2034.

The meibomian gland dysfunction market has been comprehensively analyzed in IMARC's new report titled "Meibomian Gland Dysfunction Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Meibomian gland dysfunction (MGD) refers to a set of diseases that can be either congenital or acquired and are connected by functional deviations of the meibomian glands. This condition develops when one of the several dozen small glands in the eyelids that contribute to the production of the oil layer in tears has a problem. The ailment can cause a change in the composition of the tear film, ocular surface disease, discomfort in the eyes and eyelids, and evaporative dry eye. Based on gland secretion, MGD can be classified as low or high delivery. There are no specific indications in the early stages, but as the condition progresses, the patients may experience less or poor-quality oil in the tear film, irritated, inflamed, and itchy eyelids, a feeling of sand or dust in the eye, stickiness or crusting, moments of blurred vision, burning sensations, etc. The diagnosis of this ailment is made by a review of underlying symptoms, medical history, and an initial clinical examination. Various other common procedures to confirm a diagnosis include Schirmer's test, mass spectrometry, interferometry, etc.

The rising cases of eye diseases, which cause damage and inflammation to the eyelids and cornea, are primarily driving the meibomian gland dysfunction market. Additionally, the increasing prevalence of various risk factors, such as hormonal changes, allergies, skin conditions, use of eye makeup, contact lens wear, etc., are further propelling the market growth. Moreover, the widespread adoption of effective drugs, including antibiotics, steroids, omega-3 fatty acid supplements, etc., to help reduce indications associated with the ailment is acting as another significant growth-inducing factor. Apart from this, the rising usage of non-pharmacological interventions, such as warm compresses and massage therapy, since they can ease irritation and open clogged oil glands, is also augmenting the market growth. Furthermore, the escalating demand for non-contact meibography, owing to its numerous advantages over traditional meibography, including lesser time consumption, reduced risk of infection, and minimum patient discomfort, is creating a positive outlook for the market. Besides this, the increasing utilization of vector thermal pulsation system that delivers regulated amounts of pressure and heat to clear blockages in the meibomian glands for disease management is expected to drive the meibomian gland dysfunction market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the meibomian gland dysfunction market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for meibomian gland dysfunction and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the meibomian gland dysfunction market in any manner.

Recent Developments:

• In December 2023, Azura Ophthalmics Ltd. released several presentations emphasizing good efficacy and safety findings from Phase 2 studies of their main therapeutic candidate, AZR-MD-001, in Meibomian Gland Dysfunction (MGD). This includes new, long-term data from ASCRS on the company's main medication candidate, AZR-MD-001, which demonstrated improvement in both signs and symptoms of MGD and Contact Lens Discomfort (CLD).

Key Highlights:

• It has been reported that 70% of Americans over the age of 60 have MGD.
• Caucasians have a lower prevalence than Asians, with rates ranging from 3.5-70% depending on the parameter examined.
• In India, a recent hospital-based study revealed a prevalence of 55%, and other Indian community-based investigations reported rates of around 30%.
• The prevalence of MGD rises with age.
• It tends to be higher in males than in females.

Drugs:

AZR-MD-001 uses the power of selenium sulfide in an easy-to-use ophthalmic ointment that is administered to the meibomian glands in the lower eyelid. This drug is believed to have a multi-modal mechanism of action that cures both the pathophysiology of MGD and the associated ocular surface symptoms.

CBT-008 (Cloudbreak Therapeutic) is methyl-beta-cyclodextrin given topically in repeat doses with the objective of dissolving possible cholesterol crystal deposits located in the orifice of the meibomian gland and improving tear film stability.

CBT-006 is a chemical that is capable of sequestering cholesterol. Cloudbreak Therapeutic developed this novel topical formulation using the 505b(2) regulatory process. CBT-006 used topically as eye drops in repeated doses dissolves cholesterol and other lipids deposited at the orifice of meibomian glands, improving meibum quality and gland health.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the meibomian gland dysfunction market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the meibomian gland dysfunction market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current meibomian gland dysfunction marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the meibomian gland dysfunction market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the meibomian gland dysfunction market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the meibomian gland dysfunction market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of meibomian gland dysfunction across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of meibomian gland dysfunction by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of meibomian gland dysfunction by gender across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with meibomian gland dysfunction across the seven major markets?
• What is the size of the meibomian gland dysfunction patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of meibomian gland dysfunction?
• What will be the growth rate of patients across the seven major markets?
   

Meibomian Gland Dysfunction: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for meibomian gland dysfunction drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the meibomian gland dysfunction market?
• What are the key regulatory events related to the meibomian gland dysfunction market?
• What is the structure of clinical trial landscape by status related to the meibomian gland dysfunction market?
• What is the structure of clinical trial landscape by phase related to the meibomian gland dysfunction market?
• What is the structure of clinical trial landscape by route of administration related to the meibomian gland dysfunction market?